ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
A Randomized Controlled Trial Of TENS For Movement‐Evoked Pain In Women With Fibromyalgia
Sunday 15 December 2019
A Randomized Controlled Trial of TENS for Movement‐Evoked Pain in Women with Fibromyalgia
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.1002/art.41170
Fibromyalgia (FM) is characterized by pain and fatigue, particularly during physical activity. Transcutaneous electrical nerve stimulation (TENS) activates endogenous pain inhibitory mechanisms. We evaluated if using TENS during activity would improve movement‐evoked pain and other patient‐reported outcomes in women with FM.
Participants were randomly assigned to receive active‐TENS (n=103), placebo‐TENS (n=99) or no‐TENS (n=99) and instructed to use it at home 2h/day during activity for 4‐ weeks. TENS was applied to the lumbar and cervicothoracic regions using a modulated frequency (2‐125Hz) at the highest tolerable intensity. Participants rated movement‐evoked pain (primary outcome) and fatigue on an 11‐point scale before and during application of TENS. Primary and secondary patient‐reported outcomes were assessed at randomization and 4weeks.
After 4‐weeks, the active‐TENS group reported a greater reduction in movement‐evoked pain and fatigue than placebo‐TENS (Pain, Group mean difference(95% CI): ‐1.0(‐1.8, ‐0.2), p=0.008; Fatigue: ‐1.4(‐2.4, ‐0.4), p=0.001) and no‐TENS groups (Pain: ‐1.8(‐2.6. ‐1.0), p<0.0001; Fatigue: ‐1.9(‐2.9, ‐0.9), p=<0.0001). A greater percentage of the active‐TENS group reported improvement on the global impression of change when compared to placebo‐TENS (70% vs. 31%, p<0.0001) and no‐TENS (9%, p<0.0001). There were no TENS‐related serious adverse events and less than 5% of participants experienced minor adverse events from TENS.
Among women with FM and stable medication, 4‐weeks of active‐TENS use compared with placebo‐TENS or no‐TENS resulted in a significant improvement in movement‐evoked pain and other clinical outcomes. Further research is needed to examine effectiveness in a real world, pragmatic setting to establish clinical importance of these findings.
blog comments powered by Disqus